CYP26A1 Recombinant Rabbit monoclonal Antibody IgG
Fig1: Western blot analysis of CYP26A1 on HepG2 cell lysate using anti-CYP26A1 antibody at 1/500 dilution.
Fig2: Immunohistochemical analysis of paraffin-embedded human liver tissue using anti-CYP26A1 antibody. Counter stained with hematoxylin.
Fig3: Immunohistochemical analysis of paraffin-embedded human pancreas tissue using anti-CYP26A1 antibody. Counter stained with hematoxylin.
Host Species; Species ReactivityRabbit; Human, Rat
ImmunogenRecombinant protein corresponding to human CYP26A1 aa 200-400.
Purification; FormulationProA affinity purified; 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.; Liquid form.
ALTnamesCytochrome P450 26A1, Cytochrome P450 retinoic acid-inactivating 1, Retinoic acid 4-hydroxylase, Retinoic acid-metabolizing cytochrome
BackgroundThe cytochrome P450 proteins (CYPs) are monooxygenases that catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids, and other lipids. P450 enzymes are classified into subfamilies based on their sequence similarities. CYP26A1, also referred to as retinoic acid-4-hydroxylase, is a major retinoic acid catabolic enzyme. CYP26A1 plays an important role in protecting tailbud tissues from inappropriate exposure to retinoic acid. CYP26A1 transcription is epigenetically regulated by nuclear retinoic acid receptor β2. Mutations in the gene encoding for CYP26A1 are associated with caudal agenesis and spina bifida, imperforate anus, agenesis of the caudal portions of the digestive and urogenital tracts, and malformed lumbosacral skeletal elements. CYP26A1 is upregulated in adenomatous polyposis coli mouse adenomas, human FAP adenomas, human sporadic colon carcinomas, and in the intestine of adenomatous polyposis coli (apcmcr) mutant zebrafish embryos.(ET7108-02)